Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...

While awaiting an FDA decision for its small molecule revumenib in one form of acute leukemia, Syndax Pharmaceuticals is ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on SNDX stock, giving a Buy rating yesterday. Salim Syed has given ...

Scotiabank analyst George Farmer lowered the firm’s price target on Syndax (SNDX) to $18 from $23 and keeps a Sector Perform rating on ...

Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib ...

Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) had its price target boosted by HC Wainwright from $45.00 to $47.00 in a research note issued to investors on Wednesday morning,Benzinga reports. The ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) have been given a consensus recommendation of ...

Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial ...